NTRK1 and diabetes mellitus: There are no reports, to our knowledge, regarding the effectiveness of PDGF antagonism in either the classical, remnant kidney model of chronic progressive kidney disease or in chronic diabetic nephropathy with the exception of a single report that used the multi receptor tyrosine kinase inihibitor (c-able, c-kit, PDGFR), imatinib, in the apoE knockout mouse with streptozotocin-induced diabetes, wherein proteinuria was reduced [39].